At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 43 enrolled
Drug / intervention
Switch ritonavir-boosted PI +1 moredrug
Likely dose
Continue Ritonavir-boosted PI+Rosuvastatin 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Rosuvastatin Versus Protease Inhibitor Switching for Hypercholesterolaemia in HIV-infected Adults
In Brief
A Phase 4 clinical trial evaluating Switch ritonavir-boosted PI and Continue Ritonavir-boosted PI+Rosuvastatin for HIV and Hypercholesterolaemia. Completed, enrolled 43 participants across 1 site.
Detailed Summary
To compare the effect of rosuvastatin to protease inhibitor switching on fasting total cholesterol over 12 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV, Hypercholesterolaemia
CountriesSpain
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartSep 2013
First PostedSep 2013
Primary CompletionSep 2014
TodayJul 2026
First PostedSep 5, 2013
Enrollment StartSep 1, 2013
Primary CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 12.8 years ago
Interventions
Switch ritonavir-boosted PIdrug
Switch their existing ritonavir-boosted PI to another potent ART drug with lesser effects on serum cholesterol selected by the investigator.
Continue Ritonavir-boosted PI+Rosuvastatindrug
Continue ritonavir-boosted PI-based ART and commence rosuvastatin 10 mg daily (5 mg daily in Asian participants).